Company Filing History:
5 out of 42 
1 out of 15,488 
Years Active: 1999-2006
Title: Ken N Wills: Innovator in Gene Therapy and Cell Cycle Regulation
Introduction
Ken N Wills is a notable inventor based in Encinitas, California. He has made significant contributions to the field of gene therapy and cell cycle regulation, holding a total of five patents. His work focuses on innovative methods to control cell proliferation, which has important implications for cancer treatment and other hyperproliferative conditions.
Latest Patents
One of Ken N Wills' latest patents is a method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells. This invention discloses methods for controlling cell cycle progression by introducing a composition that includes p56 protein or its gene into targeted cells. The p56 protein has been found to be soluble in low concentrations of glycerol, enhancing its pharmaceutical applications. Another significant patent involves a recombinant adenoviral vector characterized by the deletion of adenoviral protein IX DNA, which can express foreign proteins effective in regulating the cell cycle or inducing cell death.
Career Highlights
Throughout his career, Ken N Wills has worked with prominent organizations such as Canji Inc. and the University of California. His experience in these institutions has allowed him to develop and refine his innovative approaches to gene therapy and cell cycle management.
Collaborations
Ken has collaborated with notable individuals in his field, including Richard J Gregory and Daniel C Maneval. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Ken N Wills is a distinguished inventor whose work in gene therapy and cell cycle regulation has the potential to transform treatment options for various diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.